Mizartansta Tablets 80/5 mg (Telmisartan, Rosuvastatin Calcium)
Telmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
IYON Pharmaceutical Co., Ltd.
MFDS item code 202001165 · Approved 2020.02.19
This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension and dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
This medication is used in patients who require the combined use of telmisartan and rosuvastatin. Telmisartan helps reduce the risk of myocardial infarction, stroke, and cardiovascular-related mortality in patients with essential hypertension and those over 55 years old at high risk for cardiovascular disease. Rosuvastatin is used in patients with hypercholesterolemia or familial hypercholesterolemia when diet cannot control the condition, aiming to lower total cholesterol and LDL cholesterol levels and delay the progression of atherosclerosis. It is also used to reduce the risk of stroke, myocardial infarction, and vascular interventions in high-risk patients. Therefore, this medication effectively reduces the risk of cardiovascular diseases through blood pressure control and lipid improvement.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily of this medicine. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
This medication can cause significant harm to the fetus during pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, as well as lactating women, should not take this medication, and women of childbearing age should use appropriate contraception. Patients with severely impaired liver or kidney function, certain liver diseases, or muscle disorders should not take this medication. Caution is required when administering this medication to the elderly, patients with hyperkalemia, and patients with mildly impaired liver or kidney function, and regular liver function tests and muscle-related tests should be conducted. This medication may cause muscle-related side effects such as myalgia or muscle weakness, so consult a doctor immediately if there are any unusual muscle symptoms. Specifically, if muscle enzyme levels are elevated or muscle symptoms are severe, discontinue the medication, and further treatment may resume under a doctor's guidance. This medication may interact with other drugs; therefore, inform your doctor or pharmacist if you are taking other medications. Overdose may lead to hypotension, dizziness, and acute renal failure, so seek appropriate medical treatment immediately. Regular checks of liver function, kidney function, and blood potassium levels should be conducted during the medication course. Care must be taken while driving or operating machinery as this medication may cause drowsiness or dizziness. Store this medication out of the reach of children and do not transfer it to other containers.
Headache, postural dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, increased ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormality, liver disease, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitive reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, hypotension, tachycardia, bradycardia, acute renal failure, shock, loss of consciousness, liver function disorder, jaundice, symptoms resembling anaphylaxis, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, reduced efficacy, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, decreased appetite, arrhythmia, facial edema, alopecia, conjunctivitis, sound in the ears, petechiae, thrombocytopenia, increased serum creatinine, joint pain, numbness, chest discomfort, decreased appetite, abdominal distention, abnormal liver function tests, generalized pain, muscle cramps, gout
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture and should be kept at room temperature between 1 and 30 degrees Celsius. Maintaining the proper temperature can help prolong the medication's effectiveness.
Bright pink oval film-coated tablets
30 tablets/box [10 tablets/PTP*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Telmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
IYON Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.